Nyxoah is trading 8.78% up now at $1.43 as investors continue assessing its August 5 earnings report and August 6 call.
- Q2 revenue reached €7.7 million; U.S. revenue rose 22% sequentially to €5.2 million.
- Management reiterated €36–€40 million 2026 revenue guidance, supported by account growth, surgeon training, financing, and proposed CMS reimbursement increases.
- The rebound follows the stock’s 7.09% decline on August 6.